Internal Medicine | Page 70 of 487 | Links Medicus Content Curation & Alerts in Medicine

Study commentary | From the management of altitude sickness to congestion in acute HF: a new season for acetazolamide?

27 Oct, 2022 | 12:27h | UTC

From the management of altitude sickness to treatment of congestion in acute heart failure: a new season for acetazolamide? – European Heart Journal (free for a limited period)

Original study: RCT | Acetazolamide resulted in faster decongestion in patients with acute decompensated heart failure with volume overload.

Review | Management of NAFLD in primary care settings.

27 Oct, 2022 | 12:24h | UTC

Management of NAFLD in primary care settings – Liver International

Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – Zeitschrift für Gastroenterologie

AGA Clinical Practice Update | Diagnosis and management of nonalcoholic fatty liver disease in lean individuals.

Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group – The Lancet Gastroenterology & Hepatology (free registration required)

Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association – Arteriosclerosis, Thrombosis, and Vascular Biology

Advancing the global public health agenda for NAFLD: a consensus statement – Nature Reviews Gastroenterology & Hepatology

Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease – Gastroenterology

Non-alcoholic fatty liver disease: A patient guideline – JHEP Reports

Commentary on Twitter

Opportunities of assessment and treatment of #NAFLD in primary care settings

👉 https://t.co/cXJHFRiJVn

✍️ @VWSWong @DrJavierCrespo @JVLazarus #livertwitter #liverreviews #NASH pic.twitter.com/5SLqNvafAm

— Liver International (@LiverInt) October 23, 2022

ACR/EULAR remission criteria for rheumatoid arthritis: 2022 Revision.

26 Oct, 2022 | 14:39h | UTC

American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision – Arthritis & Rheumatology

Commentary: New ACR/EULAR Guideline Expands RA Remission Definition – MedPage Today (free registration required)

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.

26 Oct, 2022 | 14:38h | UTC

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update – Annals of the Rheumatic Diseases

Review | Hypercalcemia.

26 Oct, 2022 | 14:37h | UTC

Hypercalcemia: A Review – JAMA (free for a limited period)

Author Interview: Hypercalcemia—A Review – JAMA

Optimizing medication use in older adults with rheumatic diseases: deprescribing as an approach when less may be more.

26 Oct, 2022 | 14:33h | UTC

Optimizing Medication Use in Older Adults With Rheumatic Musculoskeletal Diseases: Deprescribing as an Approach When Less May Be More – ACP Open Rheumatology

Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy – European Heart Journal – Cardiovascular Pharmacotherapy

Deprescribing in Older Adults with Cardiovascular Disease – Journal of the American College of Cardiology

Multimorbidity in Older Adults with Cardiovascular Disease – American College of Cardiology, Latest in Cardiology

Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis – Health Technology Assessment

Antihypertensive Deprescribing in Older Adults: a Practical Guide – Current Hypertension Reports

How-to guide for medication reviews in older adults with cancer: A Young International Society of Geriatric Oncology and Nursing & Allied Health Interest Group initiative – Journal of Geriatric Oncology

Deprescribing in Palliative Cancer Care – Life

Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review – Kidney360

Process evaluation of implementation strategies to reduce potentially inappropriate medication prescribing in older population: A scoping review – Research in Social and Administrative Pharmacy

AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review – Gastroenterology

Development of a Metric to Detect and Decrease Low-Value Prescribing in Older Adults – JAMA Network Open

The MedSafer Study—Electronic Decision Support for Deprescribing in Hospitalized Older Adults: A Cluster Randomized Clinical Trial – JAMA Internal Medicine

Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models – Drugs & Aging

Deprescribing in palliative patients with cancer: a concise review of tools and guidelines – Supportive Care in Cancer

Prescribing practices, patterns, and potential harms in patients receiving palliative care: A systematic scoping review – Exploratory Research in Clinical and Social Pharmacy

A narrative review of evidence to guide deprescribing among older adults – Journal of General and Family Medicine

Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens – The Lancet Health Longevity

Polypharmacy Management in Older Patients – Mayo Clinic Proceedings

Psychopharmacological Treatment in Older People: Avoiding Drug Interactions and Polypharmacy – Deutsches Ärzteblatt international

Eliminating Medication Overload: A National Action Plan – Lown Institute

International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position Statement and 10 Recommendations for Action – Drugs & Aging

Common ED Medication Errors: Polypharmacy – emDocs

Current and future perspectives on the management of polypharmacy – BMC Family Practice

Routine deprescribing of chronic medications to combat polypharmacy – Therapeutic Advances in Drug Safety

Polypharmacy—an Upward Trend with Unpredictable Effects – Deutsches Ärzteblatt international

Clinical Consequences of Polypharmacy in Elderly – Expert Opinion on Drug Safety

M-A | Age, sex, race, BMI, and duration of type 2 DM differences in cardiovascular outcomes with glucose lowering drugs.

26 Oct, 2022 | 14:32h | UTC

Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis – eClinicalMedicine

Commentary: Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection – medwire News

New horizons in Type 2 myocardial infarction: pathogenesis, assessment and management of an emerging geriatric disease.

26 Oct, 2022 | 14:27h | UTC

New horizons in Type 2 myocardial infarction: pathogenesis, assessment and management of an emerging geriatric disease – Age and Ageing

M-A | Non-pharmacologic and pharmacologic treatments for anxiety in long-term care.

26 Oct, 2022 | 14:26h | UTC

Non-pharmacologic and pharmacologic treatments for anxiety in long-term care: a systematic review and meta-analysis – Age and Ageing

RCT | In critically ill patients receiving MV, there was no difference in outcomes between different O2 saturation targets.

25 Oct, 2022 | 13:23h | UTC

Oxygen-Saturation Targets for Critically Ill Adults Receiving Mechanical Ventilation – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Study finds that the most common oxygen saturation targets for hospitalized patients appear equally safe and effective – Vanderbilt University Medical Center

Effect of Low-Normal vs High-Normal Oxygenation Targets on Organ Dysfunction in Critically Ill Patients: A Randomized Clinical Trial – JAMA

Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure – New England Journal of Medicine

Oxygen targets – Intensive Care Medicine (if the link is paywalled, try this one)

Thoracic Society of Australia and New Zealand Position Statement on Acute Oxygen Use in Adults: ‘Swimming between the flags’ – Respirology

Long-term mortality and health-related quality of life of lower versus higher oxygenation targets in ICU patients with severe hypoxaemia – Intensive Care Medicine

Oxygen Targets During Mechanical Ventilation in the ICU: A Systematic Review and Meta-Analysis – Critical Care Explorations

Higher versus lower oxygenation strategies in the general intensive care unit population: A systematic review, meta-analysis and meta-regression of randomized controlled trials – Journal of Critical Care

Commentary on Twitter

In this trial involving patients receiving mechanical ventilation, randomly assigned low, intermediate, or high oxygenation targets did not alter the number of ventilator-free days. @CritCareReviews https://t.co/UUxrEPRxs6 pic.twitter.com/ueUSX8ZmHG

— NEJM (@NEJM) October 24, 2022

ASMBS Guidelines | Indications for metabolic and bariatric surgery.

24 Oct, 2022 | 14:17h | UTC

2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery – Surgery for Obesity and Related Diseases

News Release: After 30 years — new guidelines for weight-loss surgery – American Society for Metabolic and Bariatric Surgery

Commentary: New guidelines expand eligibility for weight loss surgery. Will insurance coverage follow? – USA Today

Commentary on Twitter

✴️ Updated Indictions of #BariatricSurgery for treating #obesity by @ASMBS @IfsoSecretariat https://t.co/TrTcCEu0q1 pic.twitter.com/c5s15FmXpp

— Ali Aminian (@Ali_Aminian_MD) October 21, 2022

KDIGO 2022 Clinical practice guideline for diabetes management in chronic kidney disease.

24 Oct, 2022 | 14:16h | UTC

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease – Kidney International

RCT | Ivermectin does not improve time to recovery in outpatients with mild to moderate COVID-19.

24 Oct, 2022 | 14:14h | UTC

Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial – JAMA

Commentary: Ivermectin doesn’t speed time to recovery from nonsevere COVID – CIDRAP

Commentary on Twitter

Study findings do not support the use of #ivermectin in outpatients with mild to moderate #COVID19. https://t.co/do8zbVkeLK #Research

— JAMA (@JAMA_current) October 21, 2022

Post-trial follow-up | Microbiome therapeutic SER-109 through 24 weeks for recurrent Clostridioides difficile infection.

24 Oct, 2022 | 14:15h | UTC

Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial – JAMA (free for a limited period)

Original Study: RCT: Among patients with recurrent Clostridioides difficile infection, the use of SER-109, an oral microbiome therapy, reduced recurrence rate compared to placebo (12% vs. 40%).

Commentary on Twitter

SER-109, an investigational microbiome therapeutic comprised of purified Firmicutes spores, durably reduced recurrent Clostridioides difficile infection rates and was well-tolerated through 24 weeks in patients with prevalent comorbidities. https://t.co/abayN0iJ5z

— JAMA (@JAMA_current) October 19, 2022

Systematic Review | Antidepressants for hip and knee osteoarthritis.

24 Oct, 2022 | 14:04h | UTC

Antidepressants for hip and knee osteoarthritis – Cochrane Library

Systematic Review | Systemic corticosteroids for radicular and non‐radicular low back pain.

24 Oct, 2022 | 14:03h | UTC

Systemic corticosteroids for radicular and non‐radicular low back pain – Cochrane Library

AGA clinical practice guideline on pharmacological interventions for adults with obesity.

21 Oct, 2022 | 13:06h | UTC

AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity – Gastroenterology

News Release: First medical guideline recommends new prescription medications for weight loss, ranks the most effective drugs – American Gastroenterological Association

Brief Review | Management of oliguria.

21 Oct, 2022 | 13:04h | UTC

Management of oliguria – Intensive Care Medicine (if the link is paywalled, try this one)

Commentary on Twitter

Oliguria relatively frequent in #ICU & perioperative setting, but most episodes not followed by #AKI:
➡️ physiological vs pathological
➡️ impact
➡️ management
Even if clinically important, interpret isolated oliguria with caution, considering context.
🗞️ https://t.co/xVs2Wa3mgB pic.twitter.com/4pX4UcHY1R

— Intensive Care Medicine (@yourICM) October 21, 2022

Case-control study | Post-paracentesis ascitic fluid leak in patients with cirrhosis of liver and its management.

21 Oct, 2022 | 12:57h | UTC

Post-Paracentesis Ascitic Fluid Leak in Patients with Cirrhosis of Liver and its Management: A Prospective Study – Journal of Clinical and Experimental Hepatology

Review | Update on the management of upper gastrointestinal bleeding.

20 Oct, 2022 | 12:29h | UTC

Update on the management of upper gastrointestinal bleeding – BMJ Medicine

Cohort Study | Intravenous potassium and magnesium linked to spontaneous conversion of atrial fibrillation in the ED.

20 Oct, 2022 | 12:27h | UTC

Association of Intravenous Potassium and Magnesium Administration With Spontaneous Conversion of Atrial Fibrillation and Atrial Flutter in the Emergency Department – JAMA Network Open

Commentary on Twitter

IV potassium and magnesium was associated with higher rates of conversion in atrial fibrillation but not flutter during patients’ emergency department stays. https://t.co/p3nQK8zNMs

— JAMA Network Open (@JAMANetworkOpen) October 19, 2022

Cohort Study | Associations of hypertriglyceridemia onset age with cardiovascular disease and all‐cause mortality in adults.

20 Oct, 2022 | 12:25h | UTC

Associations of Hypertriglyceridemia Onset Age With Cardiovascular Disease and All‐Cause Mortality in Adults: A Cohort Study – Journal of the American Heart Association

M-A of RCT | Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis.

20 Oct, 2022 | 12:25h | UTC

Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis – Journal of Hepatology (link to abstract – $ for full-text)

Commentary on Twitter

#Carvedilol
➡️non-selective #βblocker
✅associated with reduced risk of decompensating events
➡️improved survival in patients with #cirrhosis & #portalhypertension

Read it here👉https://t.co/yy8DIJBhfL #LiverTwitter pic.twitter.com/XxmrB7gff8

— Journal of Hepatology (@JHepatology) October 13, 2022